S. pyogenes

Recombinant Cas9 with double-ended NLS expressed by E.coli

10 mg/mL

GenCRISPR™ Ultra eSpCas9-2NLS is a mutant form of Cas9 nuclease and is produced by expression in an E. coli strain carrying a plasmid encoding the eSpCas9 gene from Streptococcus pyogenes with double-ended nuclear localization signal (NLS). GenCRISPR™ Ultra eSpCas9-2NLS delivers higher fidelity and less off-target activity than wild-type SpCas9 nuclease.

S. pyogenes

Recombinant eSpCas9 with an N-terminal NLS expressed by E.coli

10 mg/ml

GenCRISPR™ Ultra eSpCas9-N-NLS Research, tag-free is a mutant form of Cas9 nuclease and is produced by expression in an E. coli strain carrying a plasmid encoding the eSpCas9 gene from Streptococcus pyogenes with an N-terminal nuclear localization signal (N-NLS). GenCRISPR™ Ultra eSpCas9-N-NLS Research, tag-free delivers higher fidelity and less off-target activity than wild-type SpCas9 nuclease.

GenCrispr eSpCas9 nuclease is a mutant form of Cas9 nuclease. Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9system. Compared with the wild type Cas9 nuclease, eSpCas9 reduces off-target effects by over 10-fold, while maintaining robust on-target genome editing efficiency. GenScript has developed a eSpCas9-N-NLS nuclease which contains a nuclear localization sequence (NLS) on the N-terminus of the protein to meet all the researchers’ requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).